Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 22, 2022, furnishes unaudited financial statements for the three and six months ended June 30, 2022. The filing is necessary because the Company's prior independent registered public accounting firm terminated its relationship effective August 5, 2022. Consequently, the financial statements have not been reviewed by an independent auditor and are subject to change. The Company is a clinical-stage biopharmaceutical firm focused on personalized cancer treatment using its Drug Response Predictor (DRP) platform.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 (Restated) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7.7) million | $(8.5) million |
| Net Loss Attributable to Common Stockholders | $(9.3) million | $(8.5) million |
| Cash and Cash Equivalents (June 30, 2022) | $7.6 million | $19.6 million (Dec 31, 2021) |
| Accumulated Deficit | $(74.2) million | $(66.5) million (Dec 31, 2021) |
| Net Cash Used in Operating Activities | $(9.7) million | $(6.8) million |
| Total Liabilities | $12.9 million | $30.8 million (Dec 31, 2021) |
Note: The Company reported no revenue for the periods presented. Operating expenses were $22.6 million for the six months ended June 30, 2022, driven significantly by a $14.0 million impairment charge on intangible assets.
Material Changes and Unusual Items
- Intangible Asset Impairment: The Company recognized a non-cash impairment charge of $14.0 million during the six months ended June 30, 2022. This was triggered by a Refusal to File (RTF) from the FDA regarding the New Drug Application (NDA) for dovitinib and a depressed stock price.
- Derivative Liability Adjustments: The Company recorded a $13.4 million gain from the change in fair value of derivative and warrant liabilities. This gain was offset by an $800,000 penalty on Series A Preferred stock liability and a $1.5 million floor price adjustment liability paid in cash upon conversion of preferred stock.
- Restatement of Prior Periods: Financial statements for the three and six months ended June 30, 2021, were restated to correct errors related to warrant valuation, unrecorded promissory notes, and deferred tax valuation allowances.
- Management Changes: In June 2022, the CEO and CFO resigned. James Cullem was appointed Interim CEO, and Joan Brown was appointed Interim CFO.
Guidance, Outlook, and Risks
Strategic Pivot: On August 2, 2022, the Board mandated a refocus of the oncology pipeline strategy away from monotherapies toward combination therapies. The Company determined that advancing dovitinib as a monotherapy in adults is no longer commercially viable due to FDA feedback requiring new dosing studies. The Company plans to initiate a Phase 1b/2 study of stenoparib in combination with dovitinib for metastatic ovarian cancer by Q4 2022.
Liquidity and Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern. As of August 18, 2022, cash on hand ($7.6 million) is insufficient to fund operations for the next 12 months. The Company is seeking additional funding through equity, debt, or partnerships, with no assurance of success.
Delisting Risk: The Company is currently delinquent in filing its Form 10-Q for the quarter ended June 30, 2022, due to the lack of an independent auditor. Failure to meet Nasdaq listing requirements could result in delisting, which would adversely affect the stock price and ability to raise capital.
Accounting Uncertainty: The unaudited financial statements are subject to change upon review by a new independent auditor. Additionally, the Company is reassessing the value of its assets, including intangible assets, which could materially affect the financial statements.
Investor Verification Checklist
- Going Concern Status: Verify the Company's progress in securing additional funding to sustain operations beyond the current cash runway.
- Auditor Engagement: Confirm the appointment of a new independent registered public accounting firm and the subsequent filing of the Form 10-Q for the quarter ended June 30, 2022.
- Nasdaq Compliance: Monitor the Company's status regarding Nasdaq listing requirements and any potential delisting notices.
- Asset Valuation: Review the final audited financial statements for potential adjustments to the $14.0 million impairment charge and the valuation of intangible assets.
- Series A Preferred Stock: Assess the impact of the "Triggering Event" and subsequent forbearance agreements with 3i, LLP, including potential redemption rights and dividend accruals.